
Presenting Companies
Apply to pitch your cardiovascular innovation company to Octane’s ecosystem of investors.

Apply to Pitch at CTS 2023!
Do you have an innovative cardiovascular company seeking capital? The final session at our Cardiovascular Tech Summit will feature top Cardiovascular innovation companies, providing an opportunity to pitch directly to our investors. Apply to present at Octane’s Cardiovascular Tech Summit!
Past Presenting Companies
Covellus
Covellus is at the forefront of an imminent paradigm shift from conventional unitary catheter designs to agile Modular Catheter Systems for endovascular and other minimally invasive procedures. Think bigger than one product, think new categories of catheter solutions and product families.
Our patented Modular Catheter Architecture will empower physicians, manufacturers, and healthcare systems to do more with less by replacing conventional unitary catheter designs with our intuitive, and elegant Modular Catheter Systems.
The first product using the Modular Catheter Architecture is the Modular Balloon System (MBS), ushering in a new era for PAD balloon catheters.
Indian Wells Medical, Inc. (IWM)
Indian Wells Medical, Inc. is a self-funded Med-Tech company located in Orange County, California. The company is focused on leveraging its proprietary steerable transcatheter technology platform to make systems which improve delivery of therapeutic and diagnostic devices. The Company is seeking growth capital to expand marketing and manufacturing.
The Company’s FlexPoint® steerable transseptal needle, is already cleared for marketing in the US (Class II) and Europe (CE Mark). This is the only known steerable needle in existence and targets a worldwide market of over 350,000 units annually, and growing. The device has been used in over 1,000 clinical cases.
JVP Labs
Home-based care of CHF patients typically relies on physical markers like blood pressure, weight gain and symptoms which do not predict disease progression. This results in readmission rates greater than 25% within 30 days. Implanted pressure monitors have proven to reduce readmission rates after discharge, but are costly and require surgery.
JVP is the cornerstone of in-hospital management of CHF patients. It is a direct measure of pressure inside the heart and predicts worsening symptoms. JVPLabs has automated the capture of the JVP (and other vital signs) in an easy to use, cost effective and non-invasive device, facilitating effective monitoring in hospital and home.
NXT Biomedical
NXT Biomedical is an incubator of medical technologies, working in areas of disproportionate impact to patients and the healthcare system. NXT has developed a subcutaneous, multi-parameter sensor which measures a pressure in the interstitial space that has a direct relationship to invasive hemodynamic pressures traditionally obtained by providers managing heart failure patients. The NXT IFPx sensor, and associated patient management platform, form a system that provides this novel pressure, alongside a suite of established physiologic variables to empower providers with trending, multiparametric, and continuous data for therapeutic titration to reduce HF admissions with little to no patient involvement.
